PLEASE NOTE: CanView Enquiries and Burleigh Heads Cannabis will be closed Friday 26th August for Gold Coast Show Day Public Holiday. Place urgent orders before 1pm (AEST) on Thursday 25th August.

Medical Cannabis Distributor

Our Product Partners

Burleigh Heads Cannabis partners with leading domestic and international wholesale producers and suppliers with the goal to provide Australian patients with the widest range of medical cannabis products in the country. We ensure that every supply partner we work with aligns with our core values and we work closely with them to make sure that all the medical cannabis products listed on CanView have reliable supply and conform to the highest quality standards. 

If you are a cultivator, manufacturer, wholesaler or brand looking for Australian market distribution of wholesale medical marijuana therapies or to increase your growth profile through our proven strategies, please get in touch with our team today. We look forward to speaking with you. 

Register Now to Start Placing Orders



Tilray (NASDAQ:TLRY)

Established in 2013, Tilray was the first GMP-certified medical cannabis producer to supply cannabis extract products to thousands of patients, physicians, pharmacies, hospitals, governments, and researchers across four continents. As a North American manufacturer based out of Canada, Tilray has GMP production facilities located in Namaimo, British Columbia and Catehande, Portugal. In 2017, Tilray Australia and New Zealand was established and since then has been dedicated to supporting the ANZ region with access to its GMP medicinal cannabis products.

Tilray was the first company to legally export medicinal cannabis from North America to Australia and New Zealand. Today, it is one of the leading providers of medicinal cannabis in Australia and New Zealand for commercial, compassionate access and research purposes.

NSW, Australia

Cronos Australia: (ASX:CAU)

Committed to providing Australian patients access to the highest quality medicinal cannabis products, Cronos Australia’s vision is to become a leading health and wellness company in the Asia Pacific region with a portfolio of cannabinoid products. The Company’s business model is underpinned by the development of innovative products and brands, outsourced manufacturing, as well as distribution networks for the Australia market and beyond.

Cronos Australia’s flagship brand is the Adaya medicinal cannabis range. Adaya products have been designed, developed and formulated based on feedback from patients and healthcare professionals to meet their needs throughout Australia. The Adaya range also places an important focus on low product costs, further strengthening the goal of sustainable patient access.

NSW, Australia

Little Green Pharma (ASX:LGP)

As the first Australian company to grow and produce Australian medical-grade cannabis oil, Little Green Pharma (LGP) has been assisting patients since 2018 with a vision to transform the lives of patients globally. LGP produces locally manufactured, quality cannabis medicines that are AU GMP-certified. It stands proudly behind the Made in Australia stamp having experienced first-hand the strict quality requirements for medicinal cannabis products grown and manufactured locally to Australian standards, and the assurance this gives to both doctors and patients.

The Little Green Pharma team has proven their commitment to helping patients, demonstrated through not only the quality, reliability, and affordability of their products, but the level of service they provide too. In addition, Little Green Pharma also works closely with medical practitioners to assist them with applications for medical cannabis products.

WA, Australia

BOD Australia (ASX:BOD)

BOD Australia (BOD) is an ASX-listed company committed to providing the highest quality cannabinoid extracts to support patient care. Launched in 2014 with a vision to innovate and create herbal-based healthcare products, BOD’s products unify the strengths that both science and herbal medicine have to offer. The Company’s ongoing aim is to provide its customers with high-grade ingredients and apply evidence-based scientific rigour and clinical trial processes to ensure tangible solutions for all.

BOD has collaborated with world-renowned manufacturers to provide GMP pharmaceutical-grade medicinal cannabis under its MediCabilis range. Its ongoing partnerships with prominent global researchers, doctors and institutions enable BOD to build knowledge and evidence to support the use of medical cannabis. Distributing products in Australia and the UK, BOD is a trusted leader in medical cannabis products for both the consumer and medical markets.

NSW, Australia

Australian Naturals Therapeutics Group (ANTG)

As a privately owned Australian company, ANTG combine strong research with premium cultivation and extraction methods to develop high-quality cannabinoid medicines for treatments that meet individual patient needs. All ANTG products are Australian grown and made with a variable ratio of CBD and THC. ANTG is committed to investing in research and development, both in-house and by partnering with key universities to undertake cannabis research and support clinical trial programs. The ANTG team asserts that they have witnessed first-hand the ability of medical cannabis to relieve chronic and debilitating disease symptoms in areas whereby traditional treatments lack efficacy or have significant side effects.

ANTG is the first and only Australian medical cannabis company to receive GMP and GACP accreditations for medicinal cannabis flower manufacturing, meeting the highest pharmaceuticals standards worldwide. Passionate about the possibilities and health benefits of medical cannabis, ANTG is dedicated to quality control at every step of the cultivation, extraction and production processes. Offering three medicinal cannabis flower strains available on prescription, ANTG’s plants are cultivated under direct sunlight in a completely natural, renewable environment that is free from harmful chemical pesticides. Using world-leading procedures that ensure optimal quality, ANTG’s Australian facilities are equipped with green water systems and specialised waste treatment methods, enabling a sustainable end-to-end process.

NSW, Australia

MGC Pharmaceuticals (ASX:MXC)

As a European based biopharma company, MGC Pharmaceuticals (MGC Pharma) develops and supplies affordable standardised phytocannabinoid derived medicines to patients across Europe, North America and Australasia. Founded by key figures in the global medical cannabis industry, MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

MGC Pharma has numerous research collaborations with world-renowned academic institutions. One of its recent research projects highlights the positive impact of using MGC Pharma-developed specific phytocannabinoid formulations in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour. MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

WA, Australia

Medcan Australia

Medcan Australia was granted the 13th Cultivation and Production license from the Office of Drug Control in November 2017 and was brought to life with a single vision – to provide Australian patients with a high quality, fair priced products. This vision has positioned the company to be a front runner in the Australia medicinal cannabis industry. Medcan Australia share a firm belief that medicinal cannabis is not simply a "one pill suits all" solution. As the Company recognise that patients have specific needs and requirements, its aim is to provide a customised product based on a patient's particular circumstances.

Deploying a vertically integrated business model, Medcan Australia cultivates and produces high quality medicinal cannabis products for both clinical trials and individual patient access. Consumers are assured quality, composition and reliability of supply thanks to automated cultivation processes designed to ensure consistent results across the board. It’s Australian-based facility has the ability to produce up to 6,500kgs of dried cannabis per annum.

QLD, Australia

Load More

Cannatrek

An Australian-owned company founded in 2015, Cannatrek specialise in the research, cultivation, manufacturing and delivery of medicinal cannabis. Backed by medicinal licenses and strategic global partnerships, the Company manages the entire product lifecycle. From growth and processing to distribution and sales, Cannatrek’s ecosystem of suppliers, doctors, pharmacists and patients is integrated by an innovative digital platform delivering information on plant-based therapies to eligible patients. Its unique seed-to-patient model supports the Company in achieving its mission to provide affordable care to patients.

Having established strong relationships with quality offshore producers, Cannatrek is able to offer premium quality cannabis varieties to its customers. Collaboration with established, leading seed banks enable Cannatrek to continuously build a genetic stock foundation of robust and rare genotypes. The Company currently has eight different plant strains and is working to develop new strains through cross-breeding to treat a wider array of medical conditions.

VIC, Australia

Beacon Medical Australia

Beacon Medical Australia (Beacon Medical) is a wholly-owned subsidiary of Canadian TSX-listed company, VIVO Cannabis (TSX:VIVO), which has been growing and selling pharmaceutical-grade medical cannabis to patients since 2014. VIVO Cannabis hold two of the first sixteen licenses granted to grow cannabis for Canadian medical patients, and Beacon Medical is a conduit for bringing the parent Company’s knowledge, care and compassion to Australian patients.

A name fit for purpose, Beacon Medical aims to be a guiding light for patients. Its indoor, small batch GMP production facilities produce premium quality, consistent products and a set of stringent quality assurance processes set the bar for quality and compliance in medicinal cannabis production. Beacon Medical’s operations house some of the most technologically advanced indoor growing facilities in the world, enabling the Company complete control over the environment and consistency of strains produced.

ON, Canada

Burleigh Heads Cannabis (BHC)

Burleigh Heads Cannabis was one of the very first companies in Australia to receive its importation and wholesale license for medical cannabis back in 2017. Since then, it has grown into one of the country’s largest and most well-known wholesalers, selling thousands of products per month to an ever-growing network of pharmacies. Adopting a patient-first philosophy, BHC’s business is built on core values of safety, affordability and reliability.

BHC partners with both domestic and international suppliers to offer pharmacies and their patients the widest range of medical cannabis products available in Australia. This provides a one-stop solution for all ordering and distribution needs.

QLD, Australia

SunCo Green

Established in 2020, SunCo Green was formed to address the need for patient access to the clinical benefits of medical cannabis, in addition to providing health professionals with product and industry information and guidance. SunCo Green’s mission is to build a locally owned and operated medical cannabis business in a socially and environmentally responsible way that will be embedded in the Australian cannabis community, plus the wider cannabis industry for years to come.

Based in Queensland's Sunshine Coast with an additional facility in South Australia, the Company offers an array of premium medical cannabis products for prescription and pharmacy customers. SunCo Green maintains that the path to success is through its partnerships with clinical, academic and key industry players. Aiming to provide a high-quality product, SunCo Green’s range is designed to be adaptable to the changing needs of its patients as the experience of its prescribers expands.

QLD, Australia

Cannim (Brand Name: Lumir)

Cannim is a global cannabis company founded in 2017 that provides GACP and GMP-certified medical solutions to deliver better physical and mental health outcomes for patients worldwide. The Business is built on three core pillars of safety, science and scale, underpinning its sustainable approach to building a global market share and establishing world-leading medicinal cannabis brands.

Since its inception, Cannim has invested in farms in Australia and Jamaica and has built a network of GMP manufacturers and alliances in education and healthcare. Cannim continues to scale its operations, enabling the ability to meet the needs of the ever-growing body of medicinal cannabis users. Pioneering industry development and leading research and education on the effects of medical cannabis, Cannim is creating new ways of administration for patients, ensuring those in need get what they require at a fair price.

NSW, Australia

SatiVite Pty Ltd

SatiVite combines decades of sustainable agricultural knowledge, medical cannabis industry expertise, and international business experience to bring patients in Australia superior medical cannabis products. All founders of SatiVite hold formal qualifications in agriculture and have in-depth, hands-on experience in growing medical cannabis, industrial hemp and other crops.

The Company scopes, imports and distributes organically and sustainably grown dried flower and broad spectrum extracts with a range of cannabinoid profiles, as well as premium cannabis-based medicines and administration devices from leading licensed suppliers. As a licensed grower and researcher, SatiVite is developing and cultivating field-grown, high-CBD varieties in Queensland and New South Wales and is ramping up to produce Australian-grown, GMP-certified medical cannabis in its own custom-engineered glass house in New South Wales.

QLD, Australia

Gamma Biomedical

A multinational organisation headquartered in Australia, Gamma Biomedical was founded in 2014 to improve access to products and services that weren’t previously available to Australian healthcare providers. The Company holds various medical wholesale licenses covering a broad spectrum of scheduled medicines in Australia. Extensive experience with international health regulations and logistics ensures governmental compliance and seamless supply chains.

In 2018, Gamma Biomedical entered a joint venture with US-based hemp company, Isospec, to create a range of Australian-specific CDB products, including Australia’s first line of flavoured oil and topical preparations. Developed in collaboration with athletes, physicians and scientists, the Isospec range is designed to maximise natural healing and recovery. From seed to final finished product, control is ensured at every stage of the process enabling constant improvement and innovation. Manufacturing under stringent GMP controls helps guarantee a premium therapeutic product for patients.

QLD, Australia

Load More

Cymra Life Sciences

Cymra Life Sciences is an Australian-owned medical cannabis cultivator and manufacturer located in Byron Bay, NSW. Established in 2017, its founders set out to improve the lives of patients through affordable, high-quality GMP medicines grown and manufactured in Australia. In addition, Cymra Life Sciences is on a mission to provide evidence that supports cannabis as a replacement for opiates.

The Company cultivates full spectrum products that are more like the plant, including terpenes and other beneficial compounds which are specialised to enhance the lives of people living in chronic and neuropathic pain. Cymra Life Sciences was one of the first Australian companies to develop medical cannabis through tissue culture propagation, a method that delivers a consistent, natural product free from chemicals and pesticides. Organic farming practices produce high-quality flower and ingredients that provide patients with the cleanest, safest and most effective products on the market.

NSW, Australia

Tikun Australia

Tikun Australia is an Australian owned licensed cultivator of medical cannabis supported by global research into plant science, manufacturing and therapeutic outcomes. The team at Tikun Australia is passionate about helping patients in need and alleviating the impact of a multitude of diseases and conditions. They are committed to providing Australian patients with greater opportunities to acquire high quality Australian cultivated and manufactured products.

Located on the Sunshine Coast in Queensland, the Business leverages its counterpart, Tikun Olam’s, substantial experience in the industry to produce premium products that target symptomatic relief for Australian patients. Tikun Olam, a global company launched over 15 years ago, is a pioneer in medical cannabis research, has performed extensive clinical trials and has assisted over 30,000 patients through its broad network of clinics.

QLD, Australia

Aruma Labs

Located in Barangaroo, NSW, Aruma Labs is a fully licensed Australian life sciences company that provides medicinal cannabis for people living with chronic illness. Driven by a passion for helping others, quality and patient care are at the forefront of the Company’s priorities. It continuously seeks to develop products and solutions that support positive health outcomes and treat unmet medical needs.

The Company develops, produces and distributes high-quality cannabinoid-based therapeutics that are manufactured to GMP standards. Each product passes through rigorous quality assurance assessments, including independent, third-party testing to meet strict Australian pharmaceutical standards. Aruma Labs also provide education and tools for healthcare providers to seamlessly integrate medicinal cannabis into clinical treatment plans for patients with chronic health conditions.

NSW, Australia

Greenlab

Based out of Lincoln University in New Zealand, Greenlab is placing the country at the forefront of medical cannabis research, production and manufacturing. Built on a mission to be an international player in cannabinoid-based medicine, Greenlab’s principal goal is to fast track research, create intellectual property and supply GMP-grade pharmaceutical products to the emergent markets in New Zealand, Australasia and North America.

The Company has received required licenses to implement research into optimising the cultivation process of medicinal cannabis, intending to reduce the cost of production, increase yield and fasten growth cycles. Greenlab’s state of the art growing facility enables the Business to apply its cultivation research effectively in an indoor, purpose-built environment. Access to unique germplasm allows the selection of elite medical cannabis clones to yield therapeutically active major and minor cannabinoids. Additionally, sophisticated intellectual infrastructure enables optimisation of agronomic parameters for elite medicinal cannabis chemovars. The Company is also committed to finding ways to transform cannabis waste value into added products.

VIC, Australia

Bloom Pharms

Since launching in 2018, Bloom Pharms has had one simple goal – to create high-quality medical cannabis products. Its aim is to revolutionise health by empowering people to take control of their health and wellbeing. By leading the way forward in education and product quality, Bloom Pharms hope to remove the stigma of cannabis and hemp by educating people on alternative health options.

From seed to shelf, the Company seeks to always maintain ethical practices. Bloom Pharms values where its products come from, as well as how they are farmed and processed. In an effort towards encouraging holistic land management and regenerative agriculture, it also actively supports certified organic and biodynamic farms. Its Pure Infusion range contains all-natural, nutrient-dense CBD oil products that are unique to the market with no chemicals or solvents used in the process. This CBD oil has an array of natural terpenes and chlorophyll, giving the oil its signature green colour.

NSW, Australia

Medibis

As an Australian cultivator, producer, manufacturer, exporter and researcher of premium cannabinoid-based therapies, Medibis is committed to delivering high-quality medicines to patients. With a passion for providing patients with the best medicine made from the best cannabis, it is focused on delivering treatment solutions using cannabinoids, flavonoids and terpenoids without the use of any nasty chemicals. Medibis is committed to providing scientific, evidence-based solutions through the research and development of medicinal cannabis to support new global treatment methods and quality of life standards.

Through research initiatives, Medibis is focused on uncovering insights into medical cannabis including phytocannabinoid therapies and the endocannabinoid system. This research, combined with cutting-edge technologies helps it deliver end-to-end solutions for clinicians and patients. With innovation to help progress cannabinoid therapy as an adjunct and disruptive treatment, Medibis is dedicated to revolutionising healthcare and transforming quality of life standards for Australian patients.

QLD, Australia

Phytoca

Phytoca is an international distributor of world-class medical cannabis products. Working in conjunction with its family business based in Switzerland, the Netherlands, Spain and Czech Republic, the company has over 35 years of experience pioneering research in cannabis genetics, seeds and strains. Phytoca has a plant-first focus, working with the best cannabis plants available to create better patient outcomes.

The company’s mission is to improve the lives of Australian patients by focusing on developing unique products containing rich cannabinoid, terpene and flavonoid profiles extracted from whole plants. By delivering better positive patient outcomes with unique products containing high concentrations of minor cannabinoids and terpenes, Phytoca aims to showcase the full therapeutic potential of cannabis to the Australian market.

VIC, Australia

Load More

Tasmanian Botanics

Tasmanian Botanics is a Tasmanian-based medicinal cannabis company that produces high-quality, affordable products. Its vision is to develop a world leading research, cultivation and manufacturing pharmaceutical facility, utilising global best practices to improve the health and wellbeing of patients. All growing and manufacturing activities are undertaken at Tasmanian Botanics’ TGA-accredited GMP facility located just outside of Hobart.

The Company produces a comprehensive range of products with various strengths, combinations and formats and is committed to providing an evidence-based approach to the efficacy and safety of its products. Building on the GMP pharmaceutical experience and skills of its technical team, Tasmanian Botanics aims to continue expanding its range to include capsules and tablets, as well as innovative delivery methods. A sustainable growing operation uses renewable energies and natural alternatives to harsh chemicals and pesticides for optimal growth.

TAS, Australia

Heyday Medical

Heyday is a 100% Australian owned, doctor-led company that focuses on developing cannabis medicines that are good for both patients and for the planet. Each of Heyday’s products are sustainably grown under the Australian sun, produced with organic compost in living soil on farms based in Victoria. With cannabis flower and oil products available for doctors to prescribe, all Heyday products are GMP certified and tested to the highest quality standards.

The company has a ‘true to plant’ approach, with a belief that the whole of the plant should be utilised for its therapeutic potential to achieve quality and complexity in all their products. To do this, Heyday is committed to carefully selecting strains based on their terpene profiles and minor cannabinoids to improve the therapeutic effects and experience for patients. Heyday specialises in producing unique product formulations that utilise lesser-known cannabinoids rarely used on the Australian market, developing strains that are optimized for specific conditions and treatments.

VIC, Australia

Hektares

Hektares is a global cannabis company with operations across Australia and the USA. Formed in Australia by a talented group of entrepreneurs, Hektares believes in partnering and investing in best-in-class companies, making a number of strategic investments which help enable a global vision.

Hektares is dedicated to the innovation, development and commercialisation of cannabis, globally. The company produces a range of products under their brand name, Revive Biotech. Each of their products are researched, formulated, and lab-tested for safety, homogeneity and shelf-stability. Led by pain management doctors, pharmacologists, and organic chemists, Hektares ensures that their products not only work effectively, but are also affordable to the consumer.

Using patented technologies, pharmaceutical-grade input material and innovative ingredients, their products allow for faster delivery and high bioavailability, with complete preservation of cannabinoids and terpenes. The company’s aim is to break through the market with well-researched and high-tech products that are designed to enable patients to revive, move and feel better.

VIC, Australia